DOCK4 and nonpapillary renal cell carcinoma: Further investigation indicated that high DOCK4 expression may play a crucial role in modulating the TIME, potentially enhancing susceptibility to immunotherapy and strengthening immune surveillance mechanisms.<h4>Conclusions</h4>DOCK4 is a promising prognostic biomarker in ccRCC, with high expression indicating favorable pathologic staging and improved survival.